JNJ-56022473

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, GWT-TUD GmbH

Conditions

Acute Myeloid Leukemia (AML)Lupus Erythematosus, SystemicMyelodysplastic Syndrome (MDS)

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

WithdrawnNCT02920424

Janssen Research & Development, LLCLupus Erythematosus, Systemic

Start: 2017-06-30End: 2019-09-26Updated: 2017-11-27

Phase 2

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

TerminatedNCT02992860

GWT-TUD GmbHAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

Start: 2016-07-31End: 2018-10-31Updated: 2018-10-25